15
Jan
2020
Atomwise and EQRx: Two Contrasting Strategies for the R&D Inefficiency Problem
Pharma innovation expert Bernard Munos captures the inherent inefficiency of drug development with two fascinating statistics he recently shared with me. First, for large pharmas, the average cost of developing a new drug (simply based on the total R&D costs divided by the total number of new drugs approved for sale) works out to about $5B per drug. It’s an... Read More